BRISBANE, Australia,
July 17, 2024 /PRNewswire/ -- De
Motu Cordis (DMC) today announced
plans for the next stage of development with its Contract
Development and Manufacturing Organization (CDMO) partner,
Catalent, at Catalent's Boston,
Morrisville and San Diego sites.
These expansion plans encompass services from drug product
manufacturing and device assembly through to commercial launch of
DMC's product, DMC-IH1. DMC-IH1 is an inhaled epinephrine
drug-device combination product being developed for the treatment
of anaphylaxis using a dry powder inhaler (DPI).
Catalent DPI drug delivery services offer end-to-end solutions
to bring customers through the entire clinical pharma journey by
leveraging the commercial expertise and specialty product depth
across the company's network of sites. These most recent plans
build upon the original partnership between Catalent and DMC,
initiated in November 2022.
"We are excited to build on our partnership with Catalent,
one of the world's leading CDMOs, and look forward to Catalent's
team supporting our ability to further advance DMC-IH1, through
support for drug product manufacture and dry powder inhaler
assembly," said Peter O'Neill, Chief
Executive Officer, DMC. "Catalent provides DMC with a consistency
of quality and manufacturing excellence in the United States to service global
markets."
DMC is developing DMC-IH1, a proprietary drug-device inhaler
platform technology designed specifically for indications within
emergency medicine in the community setting.
About DMC
DMC was founded in Brisbane,
Australia by Professor John
Fraser, an Intensivist and groundbreaking clinician,
researcher, and company founder. John is also founder of the
Critical Care Research Group and is a co-founder of BIVACOR. John
co-founded the COVID-19 Critical Care Consortium that facilitated
collecting over 35 million data points from ICU units worldwide and
aided in the development of treatment pathways.
Since inception, DMC has raised over US $21m in Seed rounds primarily in Australia. The majority of funding to date has
been secured via the Queensland Business Development Fund, high net
worth individuals and Australian family offices. A Series A
financing round is planned for H1 2025, which will ideally be
anchored by a US based VC.
View original
content:https://www.prnewswire.co.uk/news-releases/de-motu-cordis-dmc-announces-plans-for-the-next-stage-of-development-for-dmc-ih1-an-inhaled-epinephrine-drug-device-combination-product-302198928.html